HomeAboutRankingsData Sources
Β© 2026 GeneE
🧬
GeneE
10 sources retrieved Β· Most recent: April 2026 Β· Index updated 14 days ago
β“˜GeneE is for informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment.
AAAS
aladin WD repeat nucleoporin
Chromosome 12 Β· 12q13.13
NCBI Gene: 8086Ensembl: ENSG00000094914.15HGNC: HGNC:13666UniProt: Q9NRG9
146PubMed Papers
1Diseases
0Drugs
104Pathogenic Variants
FUNCTIONAL ROLE
Transporter
RESEARCH IMPACT
Variant-Rich
CLINICAL
OMIM Disease Gene
DATA QUALITY
βœ“ Experimental GO Evidenceβœ“ Swiss-Prot Reviewed
nucleocytoplasmic transportprotein bindingmicrotubule bundle formationmitotic spindleAchalasia-addisonianism-alacrima syndrome
✦AI Summary

AAAS encodes aladin, a WD repeat nucleoporin essential for nucleocytoplasmic transport and mitotic spindle assembly. Aladin localizes to the nuclear pore complex and regulates the proper positioning of aurora kinase AURKA and the microtubule-binding protein NUMA1, ensuring correct spindle formation and timely chromosome 12 during mitosis 1. The protein also plays critical roles in peripheral and central nervous system development 234. Mutations in AAAS cause Allgrove syndrome (Triple-A syndrome), a rare autosomal recessive disorder characterized by the classic triad of ACTH-resistant adrenal insufficiency, alacrimia (dry eyes), and achalasia (esophageal dysfunction) 56. Most mutations produce truncated ALADIN proteins, though missense and point mutations have been reported 5. Neurological manifestations, including polyneuropathy, amyotrophy, and optic atrophy, typically emerge later in disease progression as autonomic complications 57. Clinical management involves glucocorticoid and mineralocorticoid replacement for adrenal insufficiency, artificial tears for alacrimia, and pneumatic dilatation or surgical myotomy for achalasia 56. Early recognition is important as alacrimia may be the earliest disease feature, though achalasia and adrenal insufficiency are more common presenting symptoms.

Sources cited
1
AAAS is required for correct localization of AURKA and NUMA1 to ensure proper spindle formation and chromosome alignment
PMID: 26246606
2
AAAS plays a role in normal development of peripheral and central nervous system
PMID: 11062474
3
AAAS plays a role in normal development of peripheral and central nervous system
PMID: 11159947
4
AAAS plays a role in normal development of peripheral and central nervous system
PMID: 16022285
5
AAAS mutations cause Triple-A syndrome with adrenal insufficiency, alacrimia, and achalasia; most mutations produce truncated protein; neurological features include polyneuropathy, amyotrophy, and optic atrophy
PMID: 20687490
6
Allgrove syndrome presents with adrenal insufficiency, achalasia, alacrima, and can be diagnosed by genetic analysis of AAAS mutations; treatment includes hydrocortisone supplementation, artificial tears, and esophageal dilatation
PMID: 25554662
7
Allgrove syndrome is autosomal recessive caused by AAAS mutations with cardinal features of achalasia, alacrimia, and adrenal insufficiency; neurological manifestations including amyotrophy occur
PMID: 34969826
Disease Associationsβ“˜1
Achalasia-addisonianism-alacrima syndromeUniProt
Pathogenic Variants104
NM_015665.6(AAAS):c.1432C>T (p.Arg478Ter)Pathogenic
Glucocorticoid deficiency with achalasia|not provided|Neurodevelopmental disorder
β˜…β˜…β˜†β˜†2026β†’ Residue 478
NM_015665.6(AAAS):c.464G>A (p.Arg155His)Pathogenic
not provided|Glucocorticoid deficiency with achalasia
β˜…β˜…β˜†β˜†2026β†’ Residue 155
NM_015665.6(AAAS):c.446+1G>TPathogenic
not provided|Glucocorticoid deficiency with achalasia
β˜…β˜…β˜†β˜†2026
NM_015665.6(AAAS):c.57_58del (p.Tyr19_Glu20delinsTer)Pathogenic
not provided|Glucocorticoid deficiency with achalasia
β˜…β˜…β˜†β˜†2026β†’ Residue 19
NM_015665.6(AAAS):c.43C>A (p.Gln15Lys)Pathogenic
Glucocorticoid deficiency with achalasia|not provided|AAAS-related disorder|Inborn genetic diseases|Malignant tumor of esophagus
β˜…β˜…β˜†β˜†2025β†’ Residue 15
NM_015665.6(AAAS):c.936-1G>CPathogenic
not provided|Glucocorticoid deficiency with achalasia
β˜…β˜…β˜†β˜†2025
NM_015665.6(AAAS):c.1331+1G>APathogenic
Glucocorticoid deficiency with achalasia|not provided
β˜…β˜…β˜†β˜†2025
NM_015665.6(AAAS):c.1066_1067del (p.Leu356fs)Pathogenic
not provided|AAAS-related disorder
β˜…β˜…β˜†β˜†2025β†’ Residue 356
NM_015665.6(AAAS):c.1144_1147del (p.Ser382fs)Pathogenic
not provided|Glucocorticoid deficiency with achalasia
β˜…β˜…β˜†β˜†2025β†’ Residue 382
NM_015665.6(AAAS):c.479A>G (p.His160Arg)Pathogenic
not provided|Glucocorticoid deficiency with achalasia
β˜…β˜…β˜†β˜†2025β†’ Residue 160
NM_015665.6(AAAS):c.1159C>T (p.Gln387Ter)Pathogenic
not provided
β˜…β˜…β˜†β˜†2025β†’ Residue 387
NM_015665.6(AAAS):c.787T>C (p.Ser263Pro)Pathogenic
Glucocorticoid deficiency with achalasia|not provided|Spastic paraparesis;Babinski sign;Hyperreflexia|Inborn genetic diseases
β˜…β˜…β˜†β˜†2025β†’ Residue 263
NM_015665.6(AAAS):c.855_856delinsTT (p.Arg286Ter)Pathogenic
not provided|Glucocorticoid deficiency with achalasia
β˜…β˜…β˜†β˜†2025β†’ Residue 286
NM_015665.6(AAAS):c.500C>A (p.Ala167Glu)Pathogenic
not provided|Glucocorticoid deficiency with achalasia
β˜…β˜…β˜†β˜†2025β†’ Residue 167
NM_015665.6(AAAS):c.211del (p.His71fs)Pathogenic
not provided|Glucocorticoid deficiency with achalasia
β˜…β˜…β˜†β˜†2025β†’ Residue 71
NM_015665.6(AAAS):c.1024C>T (p.Arg342Ter)Pathogenic
not provided|Glucocorticoid deficiency with achalasia
β˜…β˜…β˜†β˜†2025β†’ Residue 342
NM_015665.6(AAAS):c.500C>T (p.Ala167Val)Pathogenic
not provided|Glucocorticoid deficiency with achalasia
β˜…β˜…β˜†β˜†2024β†’ Residue 167
NM_015665.6(AAAS):c.856C>T (p.Arg286Ter)Pathogenic
not provided|Glucocorticoid deficiency with achalasia
β˜…β˜…β˜†β˜†2024β†’ Residue 286
NM_015665.6(AAAS):c.938T>C (p.Val313Ala)Likely pathogenic
Glucocorticoid deficiency with achalasia
β˜…β˜…β˜†β˜†2024β†’ Residue 313
NM_015665.6(AAAS):c.1191dup (p.Glu398fs)Pathogenic
not provided|Glucocorticoid deficiency with achalasia|AAAS-related disorder
β˜…β˜…β˜†β˜†2024β†’ Residue 398
View on ClinVar β†—
Related Genes
RANBP2Protein interaction100%NUP88Protein interaction99%NDC1Protein interaction99%SEH1LProtein interaction99%NUP155Protein interaction99%NUP35Protein interaction99%
Tissue Expression

No tissue expression data available for this gene.

Gene Interaction Network
Click a node to explore
AAASRANBP2NUP88NDC1SEH1LNUP155NUP35
PROTEIN STRUCTURE
Preparing viewer…
PDB7R5K Β· 12.00 Γ… Β· EM
View on RCSB β†—
Constraintβ“˜
LOEUFβ“˜
0.92LoF Tolerant
pLIβ“˜
0.00Tolerant
Observed/Expected LoF0.74 [0.60–0.92]
RankingsWhere AAAS stands among ~20K protein-coding genes
  • #3,098of 20,598
    Most Researched146 Β· top quartile
  • #745of 5,498
    Most Pathogenic Variants104 Β· top quartile
  • #8,454of 17,882
    Most Constrained (LOEUF)0.92
Genes detectedAAAS
Sources retrieved10 papers
Response timeβ€”
πŸ“„ Sources
10β–Ό
1
Triple-A syndrome.
PMID: 20687490
Adv Exp Med Biol Β· 2010
1.00
2
Single-cell Transcriptomics Reveals Dynamic Role of Smooth Muscle Cells and Enrichment of Immune Cell Subsets in Human Abdominal Aortic Aneurysms.
PMID: 35762613
Ann Surg Β· 2022
0.90
3
Consuming personal genomics.
PMID: 31000637
Science Β· 2019
0.80
4
Elastin-elastases and inflamm-aging.
PMID: 17498549
Curr Top Dev Biol Β· 2007
0.70
5
[Familial glucocorticoid deficiency].
PMID: 17880814
Pediatr Endocrinol Diabetes Metab Β· 2007
0.60